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Abstract
Background: Observational studies have frequently reported an association between cognitive function and nutrition
in later life but randomised trials of B vitamins and antioxidant supplements have mostly found no beneficial effect. We
examined the effect of daily supplementation with 11 vitamins and 5 minerals on cognitive function in older adults to
assess the possibility that this could help to prevent cognitive decline.
Methods: The study was carried out as part of a randomised double blind placebo controlled trial of micronutrient
supplementation based in six primary care health centres in North East Scotland. 910 men and women aged 65 years and
over living in the community were recruited and randomised: 456 to active treatment and 454 to placebo. The active
treatment consisted of a single tablet containing eleven vitamins and five minerals in amounts ranging from 50–210 % of
the UK Reference Nutrient Intake or matching placebo tablet taken daily for 12 months. Digit span forward and verbal
fluency tests, which assess immediate memory and executive functioning respectively, were conducted at the start and
end of the intervention period. Risk of micronutrient deficiency at baseline was assessed by a simple risk questionnaire.
Results: For digit span forward there was no evidence of an effect of supplements in all participants or in sub-groups
defined by age or risk of deficiency. For verbal fluency there was no evidence of a beneficial effect in the whole study
population but there was weak evidence for a beneficial effect of supplementation in the two pre-specified subgroups: in
those aged 75 years and over (n 290; mean difference between supplemented and placebo groups 2.8 (95% CI -0.6, 6.2)
units) and in those at increased risk of micronutrient deficiency assessed by the risk questionnaire (n 260; mean difference
between supplemented and placebo groups 2.5 (95% CI -1.0, 6.1) units).
Conclusion: The results provide no evidence for a beneficial effect of daily multivitamin and multimineral supplements
on these domains of cognitive function in community-living people over 65 years. However, the possibility of beneficial
effects in older people and those at greater risk of nutritional deficiency deserves further attention.
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The suggestion that diet or nutrient supplements could
delay or reduce cognitive decline in later life is consistent
with the biological effects of B vitamins in lowering
homocysteine levels and of antioxidant vitamins and
minerals in protecting against tissue damage from reactive
oxygen species [1]. Cross-sectional and longitudinal stud-
ies have provided some evidence in support of associa-
tions between nutrient intake or status and cognitive
decline, though the evidence is inconsistent [1]. By con-
trast, intervention studies with antioxidant vitamins [2-5]
or B vitamins [6-8] given for 24 weeks or more in commu-
nity-living older people have found no evidence for a ben-
eficial effect of supplements, though a recent study of
subjects with raised homocysteine levels found a signifi-
cant benefit of folic acid supplementation for 3 years on
global cognitive function and two of the five component
cognitive domains [9]. Two randomised trials which used
multivitamins for 24 weeks or more also found no evi-
dence of a beneficial effect [10,11] but a small trial of frail
elderly people in residential care found a beneficial effect
of multivitamin and multimineral supplementation in
two of the five tests of cognitive function after six months
[12]. Another trial of a multivitamin and multimineral
supplement in healthy elderly subjects reported beneficial
effects after one year in six of seven tests [13], though
these findings have recently been retracted in the light of
concerns about the veracity of the data and possible con-
flicting commercial interest [14].
The MAVIS (Mineral And Vitamin Intervention Study)
trial was a large randomised, double-blind, placebo-con-
trolled trial of multivitamin and multimineral supple-
mentation designed to assess possible effects on infection
in men and women aged 65 years or over, using a supple-
ment containing eleven vitamins and five minerals [15].
In the MAVIS trial we also collected information on cog-
nitive function to assess the possible effects of multivita-
min and multimineral supplementation on cognition,
which we present in this paper.
Methods
The MAVIS trial design and recruitment has been
described in more detail elsewhere [15]. 910 men and
women aged 65 years and over who had not taken vita-
min, mineral or fish oil supplements within three months
of recruitment (one month for supplements of water-sol-
uble vitamins other than vitamin B12) were recruited from
six primary care health centres in North-East Scotland
between February and December 2002. 97% of partici-
pants in both supplemented and placebo groups were liv-
ing in the community at recruitment and all were
considered by their family doctor to be suitable for the
study. We did not exclude any participants on the basis of
impaired cognitive function, though those with dementia
were unlikely to volunteer or would have been excluded
by their doctor. We did not collect information on the
educational status of participants but this age group
would all have attended formal education for at least
seven years.
Participants were randomly allocated to receive either a
mineral and vitamin supplement or matching placebo for
12 months, with minimisation on health centre, age, gen-
der and place of residence (living in the community or in
care). 456 participants (239 men, 217 women) received
the active supplement and 454 participants (240 men,
214 women) received the placebo. The supplement con-
tained 800 μg vitamin A, 60 mg vitamin C, 5 μg vitamin
D, 10 mg vitamin E, 1.4 mg thiamin, 1.6 mg riboflavin, 18
mg niacin, 6 mg pantothenic acid, 2 mg pyridoxine, 1 μg
vitamin B12, 200 μg folic acid, 14 mg iron, 150 μg iodine,
0.75 mg copper, 15 mg zinc, and 1 mg manganese. The
participants were asked to take one tablet daily for a 12-
month period, with compliance checked by reported con-
sumption at monthly intervals. The nutrient content of
the tablet was chosen to be similar to most other com-
monly used supplements purchased over-the-counter and
the dosage was according to the manufacturers' instruc-
tions. A 10% random sample provided tablets for tablet
counting. Risk of iron, folate, vitamin C or vitamin D defi-
ciency at baseline was assessed using a simple 17 item
nutrition risk questionnaire for assessing risk of micronu-
trient deficiency in older people [16].
Cognitive function was assessed in all participants by digit
span forward and verbal fluency tests carried out face-to-
face at recruitment and over the telephone at the end of
the intervention period. The digit span forward test
requires the participant to repeat a sequence of random
digits pronounced at a rate of approximately one per sec-
ond, beginning with two sequences of two digits and con-
tinuing with two sequences of increasing length up to a
sequence of nine digits or to failures on both tests of a
shorter sequence. One point is scored for every correct
sequence repeated with a maximum score of 16 points
[17]. The verbal fluency test requires the participant to
name words beginning with each of three separate letters
in an exactly-timed one-minute period. The three letters
used (either P, R and W or C, F and L) were randomly allo-
cated at the baseline assessment and the other three letters
used at the one year assessment. The score is the total
number of words named correctly, excluding proper
nouns and words with the same start but different endings
[18].
Analyses were conducted with adjustment for baseline
values and the trial minimisation factors where appropri-
ate. Intention-to-treat analyses were conducted for trial
group comparisons. Statistical significance was basedPage 2 of 5
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planned trial sub-group analyses (those aged 75 years and
over and those at increased risk of deficiency assessed by
the nutrition risk questionnaire) the 99% confidence
interval was used to give the correct width of the 95% con-
fidence interval.
The study protocol was approved by Grampian Research
Ethics Committee and all participants gave written con-
sent to take part.
Results
The supplemented and placebo groups were well-
matched in terms of baseline characteristics (table 1). 290
participants were aged 75 years or over and 260 partici-
pants were identified as being at increased nutritional risk
at baseline. During the trial, 12 participants died, 77
stopped taking their tablets and 44 were lost to follow up.
Compliance with taking the tablets for all participants for
the whole 12-month period was over 78% in both supple-
mented and placebo groups [15].
There were no significant differences in baseline test
results between the supplemented and placebo groups in
all participants or in the two pre-planned sub-groups
(table 2). Overall there was evidence of improvement in
digit span forward test scores from baseline to 12 months
(mean change 0.4, 95% CI 0.2, 0.6) but not in the verbal
fluency scores (mean change 0.8, 95% CI -0.2, 1.7). There
was no evidence for a difference in the overall change
between the supplemented and placebo groups in either
digit span forward or verbal fluency tests. When separate
analyses were repeated for the two subgroups (those aged
75 years or over and those at risk of nutritional deficiency)
there was also no evidence for a difference between sup-
plemented and placebo groups in the digit span forward
test. However, in the verbal fluency tests in participants
aged 75 years or over there was weak evidence for a bene-
ficial effect (mean difference between supplemented and
placebo groups of 2.8 (95% CI -0.6, 6.2) units). A similar
trend was observed in the participants who were at
increased risk of nutritional deficiency (mean difference
between supplemented and placebo groups of 2.5 (95%
CI -1.0, 6.1) units).
Discussion
Overall, our results provide no evidence for a beneficial
effect of multivitamin and multimineral supplementation
on cognitive function in the majority of men and women
65 years and over living in the community. This result is
consistent with all previous studies in non-selected elderly
populations [2-10] apart from the retracted Canadian
study [13]. In the present study the doses of the vitamins
and minerals in the supplement ranged from 50–210% of
the UK reference nutrient intakea i.e. levels which could be
achieved by a well-balanced diet. Several other studies
have used higher doses, particularly of B vitamins [2-4] or
antioxidant vitamins [5-7] but none of these found a ben-
eficial effect. We considered the possibility that the partic-
ipants in the present study were unusually well nourished
but found no evidence to support this, as the proportion
of participants aged 75 years and over classified as at
increased risk of micronutrient deficiency was similar to
those in an earlier cross-sectional survey in the area [19];
in addition we excluded subjects who had been taking
dietary supplements prior to the study who were more
likely to have had better dietary intake and nutritional sta-
tus [20].
The cognitive function tests used in the present study
assessed only short term memory and executive function,
so we cannot rule out the possibility of effects in other
cognitive domains such attention and concentration. We
selected the two tests used in the present study as they
could be carried out by telephone at follow-up, but future
studies should include a wider range of tests of different
cognitive domains. We also cannot exclude the possibility
of effects of nutrients such as selenium or n-3 polyunsat-
urated fatty acids, which were not included in the supple-
ments used.
For the subgroups defined on the basis of age or nutri-
tional risk, there was weak evidence for a beneficial effect
in verbal fluency but not in the digit span forward test.
Digit span forward is a test of attention and immediate
memory involving a relatively familiar task which may be
performed relatively well even in advanced cognitive
decline, while verbal fluency tests speed of processing and
information retrieval which are sensitive to the difficulty
in generating words characteristic of Alzheimer's disease
[21]. The possibility that those at increased risk of nutri-
tional deficiency may benefit from supplements is sup-
ported by the FACIT study of men and women aged 50–
70 y with elevated homocysteine in whom there were sig-
nificant effects on global cognitive function, though for
specific cognitive domains the effects were seen in mem-
ory (assessed by recall of 15 common words) and infor-
mation processing speed (assessed by letter-digit
substitution) but not in verbal fluency (assessed by asking
the subjects to name as many animals as possible in one
minute) or in sensorimotor speed or complex speed [9].
The possibility of a beneficial effect in higher risk subjects
is also supported by the study of Dutch care home resi-
dents with a BMI less than 25 kg/m2 and median age of 83
y which found beneficial effects of multivitamins and
multiminerals in a test of short-term memory and one of
two tests of category fluency [12]. The clinical significance
of the differences in the verbal fluency test scores between
supplemented and placebo groups seen in the present
study is difficult to estimate as the tests are not widelyPage 3 of 5
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study of Canadian adults suggest that the rate of decline in
performance on this test is of the order of one point per 3
years [22]. By this estimate the difference of 2 points
observed between the supplemented and placebo groups
in the present study would be equivalent to the decline
seen over 6 years of normal aging and could therefore rep-
resent a clinically useful effect.
A limitation of this study is that we classified participants
as being at increased risk of nutritional deficiency using a
simple risk questionnaire rather than by measuring their
actual nutritional status from blood samples. The nutri-
tion assessment questionnaire used had previously been
validated by comparison with blood measures of nutrient
status in 398 community-living men and women aged 75
and over, in whom the odds ratios (95% CI) for deficiency
of iron, folate, vitamin C and vitamin D in those identi-
fied at risk by the questionnaire were 3.8 (2.0, 6.9); 5.1
(2.3; 11.3); 5.7 (3.1, 10.4) and 4.3 (1.9, 9.4) respectively
[16]. Better definition of subjects at nutritional risk could
be useful in assessing whether the effect seen in those
identified as being at nutritional risk in this study is a real
effect.
In summary, we found no evidence for a beneficial effect
of multivitamin and multimineral supplementation on
two tests of cognitive function in tests in the total sample
of participants, but cannot exclude the possibility of ben-
eficial effects in those at higher risk of nutritional defi-
ciency. In view of the high social and economic costs of
cognitive decline and the low cost of nutritional supple-
Table 2: Cognitive test scores in the supplemented and placebo groups
Participants Digit span forward scores Verbal fluency scores
Baseline Mean 
(SD)
12 months Mean 
(SD)
Supplemented vs. 




12 months Mean 
(SD)
Supplemented vs. 
placebo Mean diff. 
(95% CI)
All participants Supplemented 11.0 (2.2) (n 455) 11.5 (2.3) (n 398) -0.1 (-0.3, 0.2) 32.1 (12.0) (n 454) 33.8 (12.8) (n 397) 0.8 (-0.3, 2.0)
Placebo 11.2 (2.2) (n 450) 11.7 (2.1) (n 374) 31.7 (12.8) (n 450) 33.0 (13.3) (n 372)
Participants aged 
75 years or over
Supplemented 10.8 (2.2) (n 144) 11.1 (2.3) (n 123) -0.1 (-0.8, 0.6)1 30.0 (12.7) (n 143) 32.4 (13.0) (n 123) 2.8 (-0.6, 6.2)1
Placebo 11.0 (2.1) (n 146) 11.3 (2.2) (n 105) 29.6 (12.5) (n 146) 30.0 (13.4) (n 103)
Participants at 
increased risk of 
deficiency
Supplemented 10.8 (2.1) (n 144) 11.2 (2.4) (n 113) 0.4 (-0.3, 1.1)1 29.2 (12.0) (n 144) 31.3 (13.1) (n 113) 2.5 (-1.0, 6.1)1
Placebo 10.8 (2.2) (n 116) 10.9 (2.0) (n 91) 30.6 (13.9) (n 116) 29.2 (13.2) (n 91)
1 Reflecting the fact that the analysis was carried out on a sub-group, a 99% confidence interval was used to give the correct width for the 95% 
confidence interval.





Age in years: median (interquartile range) 72 (68.0 – 76.0) 71 (68.0 – 76.0)
Body mass index in kg/m2: mean (SD) 28.2 (4.2) 27.9 (4.1)
Women: n (%) 217 (48) 214 (47)
Current smoker: n (%) 57 (13) 63 (14)
Past or present hypertension: n (%) 188 (41) 172 (38)
Past or present heart disorders: n (%) 137 (30) 130 (29)
Past or present chest disorders: n (%) 86 (19) 87 (19)
Past or present diabetes: n (%) 37 (8) 42 (9)
Past or present cancer: n (%) 46 (10) 46 (10)
Past or present cerebrovascular disease: n (%) 31 (7) 22 (5)
At risk of iron, folate, vitamin C or vitamin D deficiency: n (%) 145 (32) 117 (26)Page 4 of 5
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mentation, further intervention studies in older people,
particularly those at increased risk of nutritional defi-
ciency, are still warranted.
Note
aNote: in the UK there are no RDAs for vitamin E, pyridox-
ine, pantothenic acid and manganese
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